Nevirapin Hexal (Nevirapine)

Nevirapine binds to a non‑nucleoside site on the HIV‑1 reverse transcriptase enzyme, causing a conformational change that blocks the enzyme’s activity. This inhibition prevents the conversion of viral RNA into DNA, thereby stopping viral replication and decreasing the amount of virus in the body.

The prescribed dose of nevirapine is individualized by the treating clinician based on factors such as patient weight, treatment history, and co‑administered drugs. Standard regimens often start with a lead‑in dose before reaching the maintenance dose, but exact numbers must be set by a qualified prescriber.

Safety data for nevirapine in pregnancy and lactation are limited. It may be used when the potential benefits to the mother outweigh potential risks to the fetus or infant, and only under close medical supervision. Breastfeeding decisions should follow local guidelines and clinician advice.

To order Nevirapin Hexal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nevirapine belongs to the NNRTI class, which directly inhibits reverse transcriptase, unlike nucleoside reverse transcriptase inhibitors (NRTIs) that act as chain terminators. Compared with protease inhibitors, NNRTIs generally have fewer drug‑drug interactions but may carry a higher risk of skin and hepatic reactions.

Nevirapin Hexal tablets should be stored at temperatures below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and avoid storing in humid environments such as bathrooms.

Nevirapin Hexal is taken orally, usually with a full glass of water. The tablets should be swallowed whole and not crushed or chewed, unless a prescriber specifically advises an alternative method for patients with swallowing difficulties.

The most serious risks include severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, and potentially life‑threatening liver injury. Early signs of rash, fever, jaundice, or abdominal pain require immediate medical evaluation and possible discontinuation of therapy.

Nevirapine is contraindicated in individuals with a known hypersensitivity to the drug or any of its components. Patients with pre‑existing severe liver disease or those who have experienced severe skin reactions to nevirapine should also avoid its use.